Related Experiment Video
Updated: Jan 31, 2026
Detection of Anti-MDA5 Autoantibodies Using HeLa Cells and Immunocytochemistry with Light Microscopy
Published on: October 31, 2025
Therapeutic Targeting of RIG-I and MDA5 Might Not Lead to the Same Rome
Dacquin M Kasumba1, Nathalie Grandvaux1
1Centre de Recherche du Centre Hospitalier de l'Université de Montréal, Montréal, QC, Canada; Department of Biochemistry and Molecular Medicine, Faculty of Medicine, Université de Montréal, Montréal, QC, Canada.
Abstract:
RIG-I and MDA5 receptors are key sensors of pathogen-associated molecular pattern (PAMP)-containing viral RNA and transduce downstream signals to activate an antiviral and immunomodulatory response. Fifteen years of research have put them at the center of an ongoing hunt for novel pharmacological pan-antivirals, vaccine adjuvants, and antitumor strategies. Current knowledge testifies to the redundant, but also distinct, functions mediated by RIG-I and MDA5, opening opportunities for the use of specific and potent nucleic acid agonists. We critically discuss the evidence and remaining knowledge gaps that have an impact on the choice and design of optimal RNA ligands to achieve an appropriate immunostimulatory response, with limited adverse effects, for prophylactic and therapeutic interventions against viruses and cancer in humans.
Insights
RIG-I and MDA5 are crucial sensors of viral RNA, triggering immune responses. Understanding their distinct roles is key to developing new antiviral and anticancer therapies using specific RNA agonists.
Area of Science:
- Immunology
- Virology
- Pharmacology
Background:
- RIG-I and MDA5 are pattern recognition receptors sensing viral RNA.
- They initiate antiviral and immunomodulatory signaling pathways.
- These receptors are central to developing new antiviral, vaccine adjuvant, and antitumor strategies.
Purpose of the Study:
- To critically review the distinct and redundant functions of RIG-I and MDA5.
- To identify knowledge gaps impacting the design of optimal RNA ligands.
- To guide the development of targeted immunostimulatory interventions.
Main Methods:
- Literature review and critical analysis of existing research on RIG-I and MDA5.
- Evaluation of evidence regarding RNA ligand design for immunostimulation.
- Discussion of implications for therapeutic and prophylactic strategies.
Main Results:
- RIG-I and MDA5 exhibit both overlapping and unique functions in sensing viral RNA.
- Specific nucleic acid agonists can modulate immune responses.
- Knowledge gaps exist in optimizing RNA ligand design for targeted effects.
Conclusions:
- Targeted use of RIG-I and MDA5 agonists holds promise for antiviral and anticancer therapies.
- Careful design of RNA ligands is essential to balance efficacy and minimize adverse effects.
- Further research is needed to fully exploit the therapeutic potential of these receptors.
Related Concept Videos
01:22Phase-lead and Phase-lag Controllers
01:13Therapeutic Index
01:30Therapeutic Communication
Verbal communication depends on language or a prescribed way of using words so that people can share information effectively. The critical aspects of verbal...
01:26Cholinergic Antagonists: Therapeutic Uses
Respiratory Tract: Ipratropium, aclidinium, and tiotropium treat asthma, chronic bronchitis, and chronic obstructive pulmonary disease (COPD). They protect against bronchoconstriction caused by irritants like cigarette smoke, sulfur dioxide, and ozone. They also help reduce nasopharyngeal...
01:29Microorganisms in Medicine and Therapeutics
01:30Adrenergic Agonists: Therapeutic Uses
Emergency and Intensive Care Unit (ICU) applications: Pressor agents increase blood pressure, heart rate, and contractility in shock and organ failure situations. Dopamine can induce vasodilation and stimulate adrenoceptors. Endogenous catecholamines are effective in treating cardiogenic shock. α2-agonists like clonidine can reverse anesthesia-induced hypertension.
Allergies and...